Online citations, reference lists, and bibliographies.
← Back to Search

The Emerging Toxicity Profiles Of Anti-CTLA-4 Antibodies Across Clinical Indications.

A. M. Di Giacomo, M. Biagioli, M. Maio
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
The promising new class of immunomodulating antibodies directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) has been extensively tested in clinical trials and found to be active against cutaneous melanoma and other tumor histotypes. Inhibition of CTLA-4 characteristically induces well-identified side effects for which the definition "immune-related adverse events" (irAEs) has been proposed. IrAEs mainly include colitis/diarrhea, dermatitis, hepatitis, and endocrinopathies; uveitis, nephritis, and inflammatory myopathy also have been reported occasionally. These unique side effects are likely a direct result of breaking immune tolerance upon CTLA-4 blockade and are generally mild, reversible, and manageable, following specific treatment guidelines that include symptomatic therapies or systemic corticosteroids. However, patient-physician communication and early treatment are also emerging as critical issues to successfully manage irAEs, thus avoiding major complications. The major experience in identifying and managing CTLA-4 treatment-related side effects has derived from studies in melanoma patients; nevertheless, accumulating clinical experiences are clearly demonstrating that irAEs are class-specific events, and that they are fully overlapping in patients with tumors of different histotypes. This review provides an overview of current safety data on CTLA-4 antagonists and of available strategies to optimize their clinical use in cancer patients.
This paper references
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
A. Pavlick (2010)
Treating cancer by targeting the immune system.
P. Hwu (2010)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
J. Lord (2009)
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
B. Rini (2011)
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
P. Zatloukal (2009)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
C. Ralph (2010)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.
J. L. Lim (2008)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
M. Akhtari (2009)
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Samer H Jaber (2006)
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
CTLA-4 and its role in autoimmune thyroid disease.
D. Chistiakov (2003)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
T. Dillard (2009)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon (2008)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E. Beck (2006)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
K. Chung (2010)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
T. Lynch (2010)
Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).
A. Harzstark (2010)
Autoimmune inflammatory myopathy after treatment with ipilimumab.
Gary R W Hunter (2009)
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy
R. Lin (2008)

This paper is referenced by
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
L. Zimmer (2015)
Checkpoint Blockade for the Treatment of Advanced Melanoma.
M. Callahan (2016)
Adverse Hair Reactions to New Targeted Therapies for Cancer.
Juan Francisco Mir-Bonafé (2019)
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Yazan Z. Alabed (2015)
Chemotherapy–Induced Colitis
C. Barcenas (2012)
Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
I. Barjaktarevic (2013)
Immune-Therapy in Cutaneous Melanoma – Efficacy Immune Markers
M. Neagu (2012)
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
E. Scott (2018)
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
G. O’Kane (2017)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati (2014)
Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
J. Cervantes (2019)
Targeted immunotherapy for non-small cell lung cancer.
M. Vasekar (2014)
Manipulating the immune response of Tasmanian Devils to target Devil Facial Tumour Disease
G. Brown (2013)
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
T. Sekiya (2019)
Drugs and Other Substances Interfering with Thyroid Function
Lucia Montanelli (2018)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
A. Marabelle (2013)
Immune checkpoint-targeted therapy: cancer and autoimmune diseases represent two sides of the same coin
N. Isakov (2016)
Sweet’s syndrome under ipilimumab therapy and a brief comparison of the cases in literature
H. A. Yasar (2020)
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma
P. Ascierto (2015)
Procédés de traitement d'un cancer positif her2
S. Y. Chui (2016)
In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
S. Tzeng (2020)
Managing Checkpoint Inhibitor Symptoms and Toxicity
Anna C Pavlick (2019)
Hepatotoxicity induced by PD-1 inhibitors in cancer treatment
A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
K. Lan (2013)
Peptide Vaccine Strategies in the Treatment of Cancer
T. J. Vreeland (2013)
Current options and future directions in the systemic treatment of metastatic melanoma.
Katja A Schindler (2014)
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
F. Torino (2012)
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
L. Brilli (2017)
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer
William Carrera (2017)
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
M. Bouchlaka (2013)
At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy
M. Callahan (2013)
CTLA-4 inhibitors in castration-resistant prostate cancer
Sumit K Subudhi (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar